First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
NCT05768139 is a phase 1/2 interventional trial sponsored by Eli Lilly and Company. As of 21 Nov 2026, it is recruiting participants. It studies Abemaciclib, Anastrozole, Exemestane, Fulvestrant and 7 more drugs in Breast Cancer and Solid Tumors, Adult. The registry lists an enrollment of 880 participants at 65 sites in 9 countries. The registry lists a start date of 17 Apr 2023 and a primary completion date of 31 Jul 2030. 4 of its registered investigators have a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT05768139 |
| Status | Recruiting |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | Eli Lilly and Company |
| Enrollment | 880 |
| Registered sites | 65 |
| Countries | 9 |
| Conditions | Breast Cancer and Solid Tumors, Adult |
| Drugs | Abemaciclib, Anastrozole, Exemestane, Fulvestrant, Imlunestrant, Letrozole, Metformin, Palbociclib, Ribociclib, Tersolisib and Tamoxifen |
| Start | 17 Apr 2023 |
| Primary completion | 31 Jul 2030 |
| Study completion | 31 Jul 2030 |
| Last update posted | 7 Jul 2026 |
| Other registry IDs | EU-CTR / CTIS (EudraCT) 2023-504807-94-00, EU-CTR / CTIS (EudraCT) 2023-000442-41 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST)
Eli Lilly and Company
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
65 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Ellison Clinic at Saint John's
Los Angeles
Reva BashoRecruiting - Recruiting
- University of Colorado Cancer Center
Aurora
Anthony EliasRecruiting
- Yale-New Haven Hospital
New Haven
Completed
- Florida Cancer Specialists Orlando/ddu
Lake Mary
Completed - Moffitt Cancer Center
Tampa
Aixa SoyanoRecruiting
- Winship Cancer Institute, Emory University
Atlanta
Manali BhaveRecruiting
- University of Iowa
Iowa City
Mark BurkardRecruiting
- Louisiana State University Health Sciences Center
New Orleans
Shou-Ching TangRecruiting
- Dana-Farber Cancer Institute
Boston
Antonio GiordanoRecruiting - Massachusetts General Hospital
Boston
Dejan JuricRecruiting
- Barbara Ann Karmanos Cancer Institute
Detroit
Terminated - Start Midwest
Grand Rapids
Manish SharmaRecruiting
- Saint Luke's Cancer Institute
Kansas City
Timothy PluardRecruiting - Washington University
St Louis
Cynthia MaRecruiting
- Memorial Sloan Kettering Cancer Center
New York
Komal JhaveriRecruiting
- Uh Cleveland Medical Center
Cleveland
Alberto MonteroRecruiting - Stefanie Spielman Comprehensive Breast Center
Columbus
Robert WesolowskiRecruiting
- Providence Cancer Institute Franz Clinic
Portland
David PageRecruiting
- the West Clinic, Pllc Dba West Cancer Center
Germantown
Gregory VidalRecruiting - Sarah Cannon Research Institute
Nashville
SMO Sarah Cannon Research Inst.Recruiting
- Mary Crowley Cancer Research Center
Dallas
Completed - Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas
Joyce O'ShaughnessyRecruiting - University of Texas Southwestern
Dallas
Nisha UnniRecruiting - University of Texas Md Anderson Cancer Center
Houston
Jordi Rodon AhnertRecruiting - Start San Antonio
San Antonio
Amita PatnaikRecruiting
- Start Mountain Region
West Valley City
William McKeanRecruiting
- Uso-Virginia Cancer Specialists, Pc
Fairfax
Alexander SpiraRecruiting
- Hospital Quiron Barcelona
Barcelona
Guzman Alonso CasalRecruiting - Hospital Universitari Vall D'Hebron
Barcelona
Cristina Saura ManichRecruiting - Instituto Oncologico Dr Rosell (ior)
Barcelona
Jose Manuel Perez GarciaRecruiting - South Texas Accelerated Research Therapeutics (start) Barcelona- Hm Nou Delfos
Barcelona
Tatiana Hernandez GuerreroRecruiting - Hospital San Pedro
Logroño
Maria Jose de Miguel LukenRecruiting - Hospital Clinico San Carlos
Madrid
Jorge Bartolome ArcillaRecruiting - Hospital Universitario Fundación Jiménez Díaz
Madrid
Bernard Doger de Speville UribeRecruiting - Hospital Universitario Hm Sanchinarro
Madrid
Juan Jose SotoRecruiting - Md Anderson Cancer Center
Madrid
Maria Calvo PlazaRecruiting - Hospital Universitario Quironsalud Madrid
Pozuelo de Alarcón
Valentina BoniRecruiting - Hospital Universitari Sant Joan de Reus
Reus
Kepa Amillano ParragaRecruiting - Hospital Universitario Virgen Macarena
Seville
Luis de la Cruz MerinoRecruiting
- Azienda Ospedaliera Nazionale Santi Antonio E Biagio E Cesare Arrigo
Alessandria
Giulia GallizziRecruiting - Spedali Civili Di Brescia
Brescia
Rebecca PedersiniNot, yet, recruiting - Istituto Europeo Di Oncologia
Milan
Giuseppe CuriglianoRecruiting - Istituto Nazionale Per Lo Studio E la Cura Dei Tumori
Milan
Giulia BianchiRecruiting - Fondazione Irccs San Gerardo Dei Tintori
Monza
Marina CazzanigaRecruiting - Azienda Ospedaliero Universitaria Pisana - Stabilimento Santa Chiara
Pisa
Carmelo BengalaRecruiting - Ospedale Santa Maria Delle Croci
Ravenna
Stefano TamberiRecruiting - Fondazione Policlinico Universitario Agostino Gemelli
Roma
Gennaro DanieleRecruiting - Centro Ricerche Cliniche Di Verona S.R.L.
Verona
Andrea ZiviRecruiting
- Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux Et Sud Ouest
Bordeaux
Maxime BrunetRecruiting - Centre Leon Berard
Lyon
Isabelle Ray-CoquardRecruiting - Institut Paoli-Calmettes
Marseille
Cecile VicierRecruiting - Centre Antoine-Lacassagne
Nice
Philippe FollanaRecruiting - Institut Claudius Regaud
Toulouse
Eleonora De MaioRecruiting - Gustave Roussy
Villejuif
Barbara PistilliRecruiting
- National Hospital Organization Kyushu Cancer Center
Fukuoka
Eriko TokunagaRecruiting - Kansai Medical University Hospital
Hirakata
Toshio ShimizuRecruiting - Kyoto University Hospital
Kyoto
TAKAKO NAKAJIMARecruiting - the Cancer Institute Hospital of Jfcr
Kōtō City
Yukinori OzakiRecruiting
- Institut Jules Bordet
Anderlecht
Philippe AftimosRecruiting - Uz Leuven
Leuven
Patrick NevenRecruiting
- Netherlands Cancer Institute
Amsterdam
Marloes G.J. van DongenRecruiting - Erasmus Mc
Rotterdam
Agnes JagerRecruiting
- Universitätsklinikum Erlangen
Erlangen
Peter FaschingNot, yet, recruiting
- Mater Misericordiae Hospital
Dublin
Austin DuffyRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT05768139
Each answer restates registry values shown on this page.
What is NCT05768139?
NCT05768139 is a phase 1/2 interventional trial sponsored by Eli Lilly and Company. It studies Abemaciclib, Anastrozole, Exemestane, Fulvestrant and 7 more drugs in Breast Cancer and Solid Tumors, Adult.
Is NCT05768139 recruiting?
As of 21 Nov 2026, it is recruiting participants. 59 of its 65 sites list their own status as recruiting.
Who leads NCT05768139?
The registry names Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) (study director, Eli Lilly and Company) as the overall official.
Where does NCT05768139 run?
The registry lists 65 sites in 9 countries. Most sites are in these countries: United States (28), Spain (12) and Italy (9).
Which drugs does NCT05768139 study?
The registered drug and biological interventions are Abemaciclib, Anastrozole, Exemestane, Fulvestrant, Imlunestrant, Letrozole, Metformin, Palbociclib, Ribociclib, Tersolisib and Tamoxifen.
When is NCT05768139 expected to complete?
The registry lists a primary completion date of 31 Jul 2030 and a study completion date of 31 Jul 2030. The sponsor last updated the record on 7 Jul 2026.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.